2023
The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study
Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.Peer-Reviewed Original ResearchConceptsContraceptive implant usersSerum etonogestrel concentrationsStrong CYP3A inducersENG implant usersEtonogestrel concentrationsMedian ageImplant usersCYP3A inducersP4 concentrationsMedian body mass indexSerum E2 concentrationsBody mass indexSignificant decreaseParticipants' median ageSuppression of ovulationSerum P4 concentrationsEffect of rifampinDrug-drug interactionsLiquid chromatography-mass spectrometry assayOnly short exposuresWilcoxon signed-rank testBaseline E2Rifampin 600Rifampin exposureRifampin therapy
2022
Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users
Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsBody mass indexPg/Median ageImplant usersEnzyme-inducing antiepileptic drugsMedian body mass indexEffects of topiramateMean percent changeParticipants' median ageOvulatory suppressionTopiramate therapyMedian durationTopiramate useEtonogestrel implantsPharmacokinetic interactionsHealthy womenAntiepileptic drugsMass indexNoninferiority studyImplant useMass spectrometry assayPercent changeDiscontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences
Novick AM, Johnson RL, Lazorwitz A, Belyavskaya A, Berkowitz L, Norton A, Sammel MD, Epperson CN. Discontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences. The European Journal Of Contraception & Reproductive Health Care 2022, 27: 212-220. PMID: 35133231, PMCID: PMC9133050, DOI: 10.1080/13625187.2022.2030702.Peer-Reviewed Original Research
2021
Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients
Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsReproductive-age womenEtonogestrel contraceptive implantContraceptive implant usersTransplant recipientsContraceptive implantsCommon transplant-related complicationPost-transplant infectionsSafe contraceptive optionTransplant-related outcomesRetrospective cohort studyTransplant-related complicationsGraft-related complicationsSide effect profileTertiary medical centerRisk of pregnancyImplant usersContraceptive implant useAdditional health risksPregnancy patternsCohort studyGraft complicationsGraft rejectionEffect profileApplicability of ancestral genotyping in pharmacogenomic research with hormonal contraception
Lazorwitz A, Aquilante C, Shortt J, Sheeder J, Teal S, Gignoux C. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clinical And Translational Science 2021, 14: 1713-1718. PMID: 33650294, PMCID: PMC8504805, DOI: 10.1111/cts.13014.Peer-Reviewed Original ResearchConceptsSelf-reported race/ethnicityHispanic/Latina ethnicityRace/ethnicityContraceptive implant usersSerum etonogestrel concentrationsEtonogestrel concentrationsLatina ethnicitySide effectsBlack/African American raceImplant usersSelf-reported black raceReproductive-aged womenNon-Hispanic raceMultivariable logistic regressionAfrican American racePharmacodynamics/pharmacokineticsHormonal contraceptionPharmacodynamic outcomesBlack race
2019
Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstetrics And Gynecology 2019, 134: 807-813. PMID: 31503152, PMCID: PMC6768730, DOI: 10.1097/aog.0000000000003452.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsOral contraceptive pillsRelated side effectsAbnormal bleedingSide effectsBleeding patternsContraceptive pillsContraceptive implantsBothersome bleedingImplant usersProspective cross-sectional studyReproductive-aged womenMultivariable logistic regressionHormonal contraceptive methodsCross-sectional studyDiscontinuation ratesEtonogestrel implantsPatient satisfactionPill prescriptionMedical recordsBleedingContraceptive methodsImplant useRelationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersBody mass indexBlack/African American raceEtonogestrel concentrationsAfrican American raceMass indexPatient characteristicsImplant useEtonogestrel levelsImplant usersAmerican raceHispanic/Latina ethnicityMedian body mass indexSerum etonogestrel levelsEtonogestrel contraceptive implantSide effect profileReproductive-age womenCertain patient characteristicsIndividual patient characteristicsMajority of womenNon-significant increaseLatina ethnicityMedian ageSerum concentrationsInfluence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsBody mass indexContraceptive implant usersEtonogestrel concentrationsSteroid hormone metabolismImplant useGenetic variantsHepatic enzyme inducersReproductive-age womenImplant usersHormone metabolismPersonalized medicine approachVariant allele frequencyOvulatory suppressionEtonogestrel implantsMass indexHormonal contraceptionConcomitant useWomen's healthPg/Medicine approachParticipant characteristicsSteroid hormonesEnzyme inducersPharmacogenomic investigations
2015
Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women?
Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women? Contraception 2015, 91: 380-385. PMID: 25684618, DOI: 10.1016/j.contraception.2015.02.003.Peer-Reviewed Original ResearchConceptsNoncontraceptive benefitsMonths of useContraceptive continuationYoung womenNew contraceptive developmentYoung women ages 13Post-visit surveysWomen ages 13Young adult womenContinuation ratesStudy participantsAdult womenGreater continuationWomenMonthsContraceptive developmentAge 13High rateContraceptionAdolescentsConcordanceBenefits leadPatientsClinicInitiation